Comparative Pharmacology
Head-to-head clinical analysis: AMCILL versus KLEBCIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMCILL versus KLEBCIL.
AMCILL vs KLEBCIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
None Documented
None Documented
1-1.5 hours in normal renal function; prolonged to 7-10 hours in anuria.
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
Renal: 60-80% unchanged; biliary: less than 10%; fecal: small amount.
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic